1) History of SARS-CoV-2 infection or with this diagnosis at the time of inclusion in the study. 2) Contact or suspect of COVID-19 at the time of inclusion. 3) Body temperature ≥ 37ºC at the time of vaccination (vaccination can be deferred up to 48 hours). 4) Acute infectious disease in the three days prior to the application of the vaccine. 5) Chronic, autoimmune or endocrine-metabolic diseases decompensated at the time of inclusion. 6) History of having received a vaccine against SARS-CoV-2 or against other coronaviruses. 7) Have received any other vaccine, in the 14 days prior to the administration of each dose. 8) Administration of any research product in the last 30 days or that its use is planned during the clinical trial. 9) Having been treated in the last 30 days or with any medical condition that requires an immunomodulator (interferon, transfer factor, biomodulin T, thymosin, etc.), steroid (except topical or inhaled) or cytostatic during the study. 10) Have received blood, immunoglobulins or blood products in the three months prior to the start of the study. 11) Known hypersensitivity to thiomersal and to any of the components of the vaccine under study. 12) Tattoos in both deltoid regions that interfere with the injection site safety assessment. 13) History or suspicion of alcoholism or drug dependence. 14) Positive urine pregnancy test, before the administration of any of the three doses in women with biological capacity to have a pregnancy (history of menarche).